肝细胞癌系统治疗与局部治疗联合及最佳序贯策略:介入放射学会基金会研究共识专家组的会议纪要
该共识专家组会议聚焦肝细胞癌系统治疗与局部治疗(LRT)的联合及最佳序贯策略,按BCLC各分期评估最迫切的研究需求。文中指出,BCLC算法已纳入新型系统药物并主张在LRT进展或肿瘤特征不利于LRT获益者中更早使用,但LRT的辅助作用及联合治疗的具体序贯方式均未被直接阐明。
要点
- 肝细胞癌诊断时多数患者不适合手术,LRT应用广泛且有强力数据支持其使用。
- BCLC算法已纳入新型系统药物,并主张在LRT进展或肿瘤特征不利于LRT获益者中更早使用。
- LRT的辅助作用及联合治疗的具体序贯方式在BCLC中均未被直接阐述。
核心结论
- 该研究共识专家组旨在突出肝细胞癌LRT与系统治疗联合及最佳序贯相关的研究优先方向,并按BCLC各分期评估最迫切的需求。
研究设计与样本
- 本文为介入放射学会基金会研究共识专家组会议纪要,评估BCLC各分期下LRT与系统治疗联合及最佳序贯的研究优先方向。
诊断标准与关键数值
- BCLC算法已纳入新型系统药物,并主张在LRT进展或肿瘤特征使其不太可能从LRT获益者中更早使用这些药物。
局限性
- 原文指出,BCLC算法中LRT的辅助作用及联合治疗的具体序贯方式均未被直接阐述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Hepatocellular carcinoma, historically, has had a poor prognosis with very few systemic options. Furthermore, most patients at diagnosis are not surgical candidates. Therefore, locoregional therapy (LRT) has been widely used, with strong data supporting its use. Over the last 15 years, there has been progress in the available systemic agents. This has led to the updated Barcelona Clinic Liver Cancer (BCLC) algorithm's inclusion of these new systemic agents, with advocacy of earlier usage in those who progress on LRT or have tumor characteristics that make them less likely to benefit from LRT. However, neither the adjunct of LRT nor the specific sequencing of combination therapies is addressed directly. This Research Consensus Panel sought to highlight research priorities pertaining to the combination and optimal sequencing of LRT and systemic therapy, assessing the greatest needs across BCLC stages.
引用
- Thornton LM, Abi-Jaoudeh N, Lim HJ, et al. Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. J Vasc Interv Radiol. 2024. PMID: 38789204. doi:10.1016/j.jvir.2024.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。